Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Intrinsic Resistance
100%
Non-small Cell Lung Cancer (NSCLC)
100%
Crizotinib
100%
ALK Inhibitor
100%
Anaplastic Lymphoma Kinase
100%
Mesenchymal-epithelial Transition Factor
100%
Alectinib
100%
Tumor Cells
21%
Fluorescence in Situ Hybridization
21%
Copy number
21%
Microtubules
21%
Treatment Lines
21%
Protein-like Substances
21%
Echinoderm
21%
Immunohistochemistry
14%
Gene Copy number
14%
Next-generation Sequencing
14%
Anaplastic Lymphoma Kinase Fusion
14%
TP53 Co-mutation
14%
Adverse Events
7%
Clinically Significant
7%
Effective Treatment
7%
Young Female
7%
Receptor Expression
7%
Objective Response
7%
Quality of Life Improvement
7%
Primary Tumor
7%
Tyrosine Kinase Inhibitor
7%
Genetic Modification
7%
Second-line Treatment
7%
Overexpression
7%
Liver Metastasis
7%
Cancer Experience
7%
Primary Resistance
7%
Diagnostic Biopsy
7%
Prolonged Response
7%
Left Lung
7%
Fluorescence in Situ Hybridization Analysis
7%
Re-biopsy
7%
Combined Therapy
7%
Symptomatic Progression
7%
Mixed Response
7%
EGFR-TKI Resistance
7%
Fusion Variants
7%
RNA Next Generation Sequencing
7%
Brigatinib
7%
Factor Inhibitors
7%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Tyrosine-Kinase Inhibitor
100%
Mesenchymal-Epithelial Transition
100%
Anaplastic Lymphoma Kinase
100%
Crizotinib
100%
Alectinib
100%
Fluorescence in Situ Hybridization
28%
Tumor Cell
21%
Next Generation Sequencing
21%
Microtubule Associated Protein
21%
Immunohistochemistry
14%
Biopsy Technique
14%
Quality of Life
7%
Adverse Event
7%
Receptor
7%
Receptor Expression
7%
Primary Tumor
7%
Liver Metastasis
7%
Gene Dosage
7%
Combined Therapy
7%
Left Lung
7%
Brigatinib
7%
Effective Treatment
7%
Genetics
7%
Pharmacology, Toxicology and Pharmaceutical Science
Intrinsic Resistance
100%
Non Small Cell Lung Cancer
100%
Protein Tyrosine Kinase Inhibitor
100%
Anaplastic Lymphoma Kinase
100%
Crizotinib
100%
Alectinib
100%
Neoplasm
21%
Microtubule Associated Protein
21%
Receptor
14%
Adverse Event
7%
Primary Tumor
7%
Liver Metastasis
7%
Brigatinib
7%
Biochemistry, Genetics and Molecular Biology
Mesenchymal-Epithelial Transition
100%
Tyrosine Kinase Inhibitor
100%
Anaplastic Lymphoma Kinase
100%
Crizotinib
100%
Fluorescence in Situ Hybridization
28%
Next Generation Sequencing
21%
Microtubule-Associated Protein
21%
Gene Dosage
7%
RNA
7%
Genomics
7%